三個皮匠報告
政策庫
new
付費
搜索

表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策-行業數據

表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策
冊。日本則要求外國生產企業通過國內代理商申請海外認定證書，并進行一系列嚴格的審查和登記程序；醫藥中間體需按照《化學物質審查與生產管理法》進行按量申報和測試。
政策法規 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?79KB 圖片尺寸：2267*790
同報告圖片
 / 37
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第1頁
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
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第2頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第3頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第4頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第5頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第6頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第7頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第8頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第9頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第10頁
fCDlubTmiqUgfCDplIDllK7otLnnlKjvvIjkuIflhYPvvIkgfCDplIDllK7otLnnlKjlj5jljJbvvIgl77yJIHwKfC0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwKfCAyMDIw5bm05oqlIHwgMTIyLjE1IHwgLTMwLjIxIHwKfCAyMDIx5bm05oqlIHwgNjEuODkgfCAtNDkuMzMgfAp8IDIwMjLlubTmiqUgfCA3OC42NyB8IDI3LjEwIHwKfCAyMDIz5bm05oqlIHwgMjAwLjAxIHwgMTU0LjI2IHwKfCAyMDI05LiJ5a2j5oqlIHwgMTMzLjIwIHwgLTE4LjU5IHwKCui1hOaWmeadpea6kO+8muWQjOiKsemhumlGaW5E77yM5rGf5rW36K+B5Yi456CU56m25Y+R5bGV6YOo
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第11頁
fCDlubTluqYgfCDnrqHnkIbotLnnlKjvvIjkuIflhYPvvIkgfCDnrqHnkIbotLnnlKjlj5jljJbvvIgl77yJIHwKfC0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tfAp8IDIwMjAgfCAxLDk3MC45MyAgICAgICAgIHwgOS44OCAgICAgICAgICAgICB8CnwgMjAyMSB8IDIsMDYyLjc1ICAgICAgICAgfCA0LjY2ICAgICAgICAgICAgIHwKfCAyMDIyIHwgMiwxNDkuNTcgICAgICAgICB8IDQuMjEgICAgICAgICAgICAgfAp8IDIwMjMgfCAyLDU1Mi4xMCAgICAgICAgIHwgMTguNzMgICAgICAgICAgICB8CnwgMjAyNCB8IDIsMTU5Ljk2ICAgICAgICAgfCAxNS43NCAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muWQjOiKsemhumlGaW5E77yM5rGf5rW36K+B5Yi456CU56m25Y+R5bGV6YOo
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第12頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第13頁
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
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第14頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第15頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第16頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第17頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第18頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第19頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第20頁
fCDml7bpl7QgfCDkurrlj6PmlbDvvIjkuIfkurrvvIkgfCDmr5Tph43vvIgl77yJIHwKfC0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS18CnwgMTk1M+W5tCB8IDI2MjEgfCA0LjQxIHwKfCAxOTgy5bm0IHwgNDkyNyB8IDQuOTMgfAp8IDE5OTDlubQgfCA2MzAwIHwgNS41NyB8CnwgMTk5MuW5tCB8IDcyODUgfCA2LjA0IHwKfCAxOTk05bm0IHwgNzk1NiB8IDYuNDIgfAp8IDE5OTblubQgfCA4NjAwIHwgNi45NiB8CnwgMTk5OOW5tCB8IDkxODAgfCA3LjMzIHwKfCAyMDAw5bm0IHwgOTg4MCB8IDcuOTMgfAp8IDIwMDLlubQgfCAxMDQwOSB8IDguMzIgfAp8IDIwMDTlubQgfCAxMDkyMCB8IDguNzIgfAp8IDIwMDblubQgfCAxMTQzMyB8IDkuMTMgfAp8IDIwMDjlubQgfCAxMTk5MCB8IDkuNTMgfAp8IDIwMTDlubQgfCAxMjc2NCB8IDkuOTYgfAp8IDIwMTLlubQgfCAxMzQwMCB8IDEwLjQyIHwKfCAyMDE05bm0IHwgMTQwMDAgfCAxMC45NiB8CnwgMjAxNuW5tCB8IDE1MDAzIHwgMTEuNTUgfAp8IDIwMTjlubQgfCAxNjY1OCB8IDEyLjE0IHwKfCAyMDIw5bm0IHwgMTc4MDMgfCAxMi43MSB8CnwgMjAyMuW5tCB8IDE5MDU2IHwgMTMuNSB8CnwgMjAyM+W5tCB8IDIyMDIzIHwgMTUuNCB8CgrotYTmlpnmnaXmupDvvJrlkIzoirHpobppRmluRO+8jOaxn+a1t+ivgeWIuOeglOeptuWPkeWxlemDqA==
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第21頁
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
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第22頁
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
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第23頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第24頁
fCDlubTku70gfCDkuK3lm73ljLvoja/kuqfkuJpDRE1P5biC5Zy66KeE5qih77yI5Lq/5YWD77yJIHwKfC0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCAyMDE2IHwgMTA1ICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDE3IHwgMTMyICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDE4IHwgMTYwICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDE5IHwgMjI5ICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDIwIHwgMzE3ICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDIxRSB8IDQwMyAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyMkUgfCA1MTIgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMjNFIHwgNjM0ICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDI0RSB8IDc3NCAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyNUUgfCA5MzcgICAgICAgICAgICAgICAgICAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77ya5YWs5Y+45oub6IKh6K+05piO5Lmm77yM5rGf5rW36K+B5Yi456CU56m25Y+R5bGV6YOo
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第25頁
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
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第26頁
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
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第27頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第28頁
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
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第29頁
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
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第30頁
fCDnsbvlnosgfCDph5Hpop3vvIjkuIflhYPvvIkgfCDljaDmr5TvvIgl77yJIHwKfC0tLS0tLXwtLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tfAp8IOWbveWGhSAgfCA1LDQ3My42NyAgICAgfCAzOS44MyAgICB8Cnwg5Zu95aSWICB8IDgsMjY3LjMyICAgICB8IDYwLjE3ICAgIHwKfCDmgLvorqEgIHwgMTMsNzQwLjk5ICAgIHwgICAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77ya5ZCM6Iqx6aG6aUZpbkTvvIzmsZ/mtbfor4HliLjnoJTnqbblj5HlsZXpg6g=
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第31頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第32頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第33頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第34頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第35頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第36頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第37頁
表9、中國、韓國和日本對原料藥及醫藥中間體的監管政策_第38頁
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
所屬報告： 峆一藥業-公司研究報告-募投項目升級釋放動能CDMO業務與高毛利產品共筑未來-250416（38頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站